Breaking News

FDA Accepts RedHill Biopharma’s NDA for Talicia

Commercial launch of H. pylori treatment is planned shortly following potential FDA approval

Related CONTENT

07.16.19

RedHill Biopharma Ltd. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for Talicia (RHB-105)¹ for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.

Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDA approval. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity.

“The efficacy of current standard-of-care therapies for H. pylori bacterial infection continues to decline due to the high and steadily increasing prevalence of antibiotic-resistant strains. This public health concern is widely recognized by the U.S. government and other leading health agencies, including the World Health Organization, which classified H. pylori as a Group I carcinogen and highlighted the urgent need for new treatments for H. pylori eradication,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “The acceptance for review of the NDA for Talicia and the Priority Review designation are encouraging steps as we continue our intensive preparations for a potential U.S. commercial launch of Talicia as a new first-line, standard-of-care therapy for H. pylori. We continue to work closely with the FDA, with the aim of bringing this important new therapy to patients.”

Related Searches

Suggested For You

25 DAIICHI-Sankyo

25 DAIICHI-Sankyo

Syndax Pharma Gets IND Clearance for Leukemia Treatment

Syndax Pharma Gets IND Clearance for Leukemia Treatment

The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

Chi-Med’s Surufatinib Study Meets Primary Endpoint Early

Chi-Med’s Surufatinib Study Meets Primary Endpoint Early

FDA Approves J&J

FDA Approves J&J's DARZALEX in Multiple Myeloma

Sierra’s Momelotinib Granted FDA Fast Track Designation

Sierra’s Momelotinib Granted FDA Fast Track Designation

Risk-Based Monitoring

Risk-Based Monitoring

Aclaris Therapeutics Submits IND for RA Treatment

Aclaris Therapeutics Submits IND for RA Treatment

The Orphan Promise

The Orphan Promise

IntelGenx, Aquestive Enter ED Collaboration

IntelGenx, Aquestive Enter ED Collaboration

Dalton Pharma Services Completes PAI Inspection

Dalton Pharma Services Completes PAI Inspection

La Jolla Pharma Gets Breakthrough Designation for Malaria Treatment

La Jolla Pharma Gets Breakthrough Designation for Malaria Treatment

Recro, Teva Extend License and Supply Agreement

Recro, Teva Extend License and Supply Agreement

KASA to Support Generic Drug Review

KASA to Support Generic Drug Review

Are We Embracing FDA’s Messages?

Are We Embracing FDA’s Messages?

Related Breaking News

Breaking News | Facilities | Industry News

Parker Bioscience Opens Doors to UK Site

Investment includes extended laboratories and new clean room, manufacturing and testing facilities
08.16.19
Drug Development | Trials & Filings

Roche Wins Two Approvals for Cancer Drug Rozlytrek

Becomes third tumor-agnostic drug to win FDA Approval
08.16.19
Promotions & Moves

Marker Therapeutics Appoints Regulatory Affairs VP

Dr. Agopyan brings more than 15 years of industry knowledge in regulatory affairs and clinical development
08.16.19
cGMP Manufacture | Fill/Finish | Industry News | Parenterals

Berkshire Sterile Manufacturing Expands Capacity

To add a third isolator line with the ability to fill at a rate of 3000 units/hour
08.16.19
Trials & Filings

FDA Approves New Treatment for Drug-Resistant TB

Pretomanid is only the third new anti-TB drug approved by FDA in more than 40 years
08.15.19
Promotions & Moves

PHASTAR Appoints Head of Statistical Research

Former Oxford University Statistical Consultancy Director, Jennifer Rogers, brings to the company a broad portfolio of achievement
08.15.19
Industry News | R&D

Syapse, FDA Announce RCA Using Real-World Evidence

Focus on advancing real-world oncology endpoints and providing insight into evidence-based clinical decision-making
08.15.19
Analytical Services | Breaking News | Facilities | Industry News | Laboratory Testing

Boston Analytical Continues Expansion

Opens office in Cambridge spurred by double-digit growth
08.15.19
Breaking News | CRO News | Information Technology

SGS Launches OneVision

A digitalization initiative to standardize record-keeping procedures across all global affiliates
08.14.19
Aseptic Processing | Breaking News | Collaborations & Alliances | Fill/Finish | Industry News

SP Scientific Offers Aseptic Vial Handling Solutions

Partners with Lab-i-Dositechno to provide aseptic fill-finish lines for injectable, ophthalmic & oral products in liquid and powder form
08.14.19
Bio News | Breaking News

AskBio Acquires Synpromics

The two companies bring together pioneering technology to increase efficacy of gene therapeutics
08.14.19
Breaking News | Collaborations & Alliances | Industry News | Information Technology | Injectables

Nephron, Clemson Collaborate on Syringe-Filling Automation

The robotic solution aims to enhance sterile manufacturing in the pharmaceutical production process
08.14.19
APIs | Breaking News | Collaborations & Alliances | Industry News

CDMO Indena Improves Manufacturing Process

Jaguar Health's manufacturing partner to support expanded crofelemer manufacturing volume
08.14.19
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News

GenCure Reports Successful First Run of 80L Bioreactor

Biomanufacturing CDMO says it’s among the first to harvest adult stem cells at large scale
08.14.19
Breaking News | Facilities | Industry News

Frontage Clinical Expands NJ Facilities

Can now accommodate tobacco and nicotine-related studies
08.14.19